Literature for BMS-605339 (S29.001 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2017
1. Wang,H., Guo,C., Chen,B.Z. and Ji,M.
   Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339
   Biotechnol Appl Biochem64, 153-164. PubMed  Europe PubMed DOI  I
2014
2. Jenkins,S., Scola,P., McPhee,F., Knipe,J., Gesenberg,C., Sinz,M., Arora,V., Pilcher,G. and Santone,K.
   Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor
   J Pharm Sci103, 1891-1902. PubMed  Europe PubMed DOI  I
3. Scola,P.M., Wang,A.X., Good,A.C., Sun,L.Q., Combrink,K.D., Campbell,J.A., Chen,J., Tu,Y., Sin,N., Venables,B.L., Sit,S.Y., Chen,Y., Cocuzza,A., Bilder,D.M., D'Andrea,S., Zheng,B., Hewawasam,P., Ding,M., Thuring,J., Li,J., Hernandez,D., Yu,F., Falk,P., Zhai,G., Sheaffer,A.K., Chen,C., Lee,M.S., Barry,D., Knipe,J.O., Li,W., Han,Y.H., Jenkins,S., Gesenberg,C., Gao,Q., Sinz,M.W., Santone,K.S., Zvyaga,T., Rajamani,R., Klei,H.E., Colonno,R.J., Grasela,D.M., Hughes,E., Chien,C., Adams,S., Levesque,P.C., Li,D., Zhu,J., Meanwell,N.A. and McPhee,F.
   Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection
   J Med Chem57, 1708-1729. PubMed  Europe PubMed DOI  I